Affinium is a pharmaceutical company focused on the clinical development of antibacterials. Our lead development program encompasses a potent, orally available, novel antibiotic class for the treatment of antibiotic resistant staphylococcal infections.
For information, please contact:
Owen Roberts, CFA, Chief Financial Officer
Affinium Pharmaceuticals, Inc.
